Skip To Main Content
Shuncang Zhu on Muck Rack

Shuncang Zhu

As seen in: Wiley Online Library
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Shuncang

Contact Shuncang, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

SenExo‐cCCT2 Reprograms Senescence Response and Anti‐Tumor Immunity Following FOLFIRINOX Chemotherapy in Pancreatic Ductal Adenocarcinoma

|
By Yinhao Chen, Hongyi Lin, Jinpeng Lu, Shuncang Zhu
| Wiley Online Library Verified
1 Introduction Pancreatic ductal adenocarcinoma (PDAC) is highly malignant, and chemotherapy is the first-line treatment for progressive PDAC.[1, 2] The main treatment regimens for this disease include FOLFIRINOX (a combination regimen of 5-fluorouracil, oxaliplatin, irinotecan, and leucovorin) and AG (gemcitabine plus nab-paclitaxel).
Open in Who Shared Issue with article?
See all 1 articles